Ursodeoxycholic acid is associated with a reduction in SARS-CoV-2 infection and reduced severity of COVID-19 in patients with cirrhosis
Graphical Abstract Sample Work
COVID-19 remains a significant risk for patients with cirrhosis, who face higher mortality and limited safe treatment options due to hepatotoxicity of existing drugs. Vaccines show reduced effectiveness in immunocompromised individuals and emerging variants. Ursodeoxycholic acid (UDCA), which suppresses FXR signalling, has been shown to reduce ACE2 expression and may help prevent SARS-CoV-2 infection and severity. This study evaluates the association between UDCA use and COVID-19 outcomes in patients with cirrhosis.
Mechanism on the left, observed data on the right
This graphical abstract summarises a study by John and colleagues, published in the Journal of Internal Medicine in 2023, which found that ursodeoxycholic acid (UDCA) was associated with a reduction in SARS-CoV-2 infection and reduced COVID-19 severity in patients with cirrhosis. The layout is a straightforward two-part composition beneath a centred serif title: a schematic of the proposed biological mechanism on the left and a bar chart of the observed outcomes on the right. This pairing lets readers see both why UDCA might help and what the data showed. The audience includes hepatologists, infectious disease specialists and pharmacoepidemiologists.
Cirrhosis, COVID-19 and the ACE2 connection
People with cirrhosis have higher mortality from COVID-19 and fewer safe treatment options, partly because several antiviral and immunomodulatory drugs carry a risk of liver toxicity. Vaccines may also be less effective in immunocompromised people and against emerging variants. SARS-CoV-2 enters cells by binding the ACE2 receptor, so reducing ACE2 expression is one conceivable way to lower infection risk.
UDCA is a bile acid widely used in liver disease, including cholestatic conditions. Experimental work has indicated that it can reduce ACE2 expression by acting on farnesoid X receptor (FXR) signalling, which regulates ACE2 transcription. Because many patients with liver disease already take UDCA, its association with COVID-19 outcomes can be examined in existing clinical data.
The mechanism panel: two cell membranes compared
The left panel begins with a capsule labelled "UDCA 5mg/kg" pointing to a cirrhotic liver, establishing the patient group. Two cell surfaces are then drawn side by side. In the "Untreated" cell, FXR in the nucleus drives ACE2 transcription, and numerous ACE2 receptors line the membrane, with a SARS-CoV-2 particle nearby. In the "UDCA treated" cell, UDCA molecules surround the membrane, FXR-driven ACE2 transcription is shown as weakened by a faded dashed arrow, fewer receptors are present, and a downward arrow beside "ACE-2" summarises the change.
Presenting the two cells as mirror images makes the difference immediately apparent. The figure does not need to explain receptor biology in words, because the reduced number of receptors in the treated cell carries the message.
The bar chart: five outcomes of rising severity
The right panel is a grouped bar chart titled "Unadjusted distribution of SARS-CoV-2 infection and COVID-19 severity by UDCA receipt in participants with cirrhosis". Grey bars represent patients not receiving UDCA and blue bars those receiving it, with the y-axis in percentage. Five outcome categories run along the x-axis in increasing severity: any COVID-19, symptomatic COVID-19, moderate/severe/critical COVID-19, severe/critical COVID-19 and COVID-19-related death. In every category the blue bar is lower than the grey bar, and both decline as severity increases.
The word "unadjusted" in the chart title is important. These are crude proportions, not estimates that account for differences between people who did and did not take UDCA. The study's adjusted analyses, reported in the paper, are the appropriate basis for conclusions. Including this qualifier in the figure is good practice and prevents readers from mistaking descriptive data for an effect estimate.
The chart also uses the same blue for UDCA as the UDCA molecules in the mechanism panel, a small but effective link that helps the eye connect the proposed mechanism with the treated group's lower bars.
Interpreting an observational drug association
Studies of this kind compare patients who received a medication in routine care with those who did not. Because UDCA is prescribed for particular liver conditions, the two groups may differ in ways that affect COVID-19 risk, a problem known as confounding by indication. Observational pharmacoepidemiology studies are reported according to STROBE, and their graphical abstracts should use associative language, as this one does in its title: UDCA "is associated with" reduced infection and severity. A randomised trial would be needed to establish a protective effect. This page is a writing sample and not advice about medication use.
Applying the mechanism-plus-chart format
Pairing a mechanistic schematic with outcome data works well when an observational finding is supported by a plausible biological pathway. Label any chart as unadjusted where appropriate and keep the colours consistent with the mechanism panel. Pubrica's graphical abstract service develops such figures, and authors preparing observational drug studies can obtain a pre-submission peer review to check that causal language is avoided throughout.
Questions about this sample
How is UDCA thought to reduce SARS-CoV-2 infection?
The mechanism panel shows FXR signalling driving ACE2 expression on the cell surface. UDCA dampens this FXR-driven transcription, so fewer ACE2 receptors are available for the virus to bind. The untreated and treated cells are drawn side by side to show the difference in receptor numbers.
Why is the bar chart described as unadjusted?
The chart shows crude percentages of each outcome among patients who did and did not receive UDCA, without accounting for differences such as age, liver disease severity or other medications. The study's adjusted analyses address these factors. Labelling the chart as unadjusted prevents readers from treating it as the main effect estimate.
Does this figure show that UDCA prevents COVID-19?
No. It summarises an observational association in patients with cirrhosis, together with a proposed mechanism. The title uses the phrase 'is associated with' for this reason. Establishing a protective effect would require randomised trials, and this page is not advice about taking UDCA.
Give yourself the academic edge today
Each order includes
- On-time delivery or your money back
- A fully qualified writer in your subject
- In-depth proofreading by our Quality Control Team
- 100% confidentiality, the work is never re-sold or published
- Standard 7-day amendment period
- A paper written to the standard ordered
- A detailed plagiarism report
- A comprehensive quality report
Enquire Now
